More articles about Biomarker Discovery & Validation

Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.

The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.

The Israeli companies will use NRGene's computational tools to develop DNA-based biomarkers for medical cannabis breeding and strain identification.

The researchers analyzed whole-exome sequencing data from 249 tumors and matched normal tissue from patients with known outcomes to immunotherapy.

The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.

Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.

The predictor, based on 15 pairwise relations between immune checkpoint genes, identified almost all true responders and misclassified fewer than half of non-responders.

Diagenode said the deal will bolster its suite of epigenomics services and platforms, as well as enhance its epigenetic biomarker discovery efforts.

HTG Molecular Diagnostics offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.

Qiagen and Health Innovation Manchester will create a genomics campus in the district anchored by a diagnostics development hub.

NuMedii will use its AI technology in combination with single-cell data to identify biomarkers and therapeutics for idiopathic pulmonary fibrosis.

The funding will help support the whole-genome and RNA sequencing of Alzheimer's disease patients to advance biomarker development.

The partners have established a laboratory to investigate cell-free DNA and other bloodborne molecules as cancer biomarkers.

A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners. 

On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.

The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.

The project will focus on metabolic biomarkers that previous research has linked to heart disease, type 2 diabetes, and other common chronic diseases.

The PMSC, which formally opened last week, offers mass spectrometry and sequencing resources to help customers develop robust and scalable workflows.

As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.


Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.

Pages

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.